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Summary
Objectives: To compare the efficacy of intrapericardial 
corticosteroid therapy to either oral corticosteroid thera-
py or intrapericardial placebo in addition to closed peri-
cardiocentesis and anti-tuberculous therapy in patients 
with tuberculous pericarditis.
Methods: Patients with large pericardial effusions requir-
ing pericardiocentesis were included. A short-course 
anti-tuberculous regimen was initiated and patients were 
randomised to one of three treatment groups: 200 mg 
intrapericardial triamcinolone hexacetonide; oral pred-
nisone plus intrapericardial placebo; or 5 ml intraperi-
cardial 0.9% saline (placebo). Patients were followed up 
for at least one year. 
Results: Fifty-seven patients were included in the study; 
21 tested HIV positive (36.8%). Forty (70.0%) had 
microbiological and/or histological evidence of tubercu-
losis, and 17 (30.0%) had a diagnosis based on clinical 
and laboratory data. All patients responded well to initial 
pericardiocentesis. However, nine patients (16.0%) were 
lost to follow up. The hospitalisation duration for the 
steroid groups was shorter than for the placebo group. 
This difference was not significant. Complications were 
similar for all arms. 
Conclusions: Intrapericardial and systemic corticoster-
oids were well tolerated but did not improve the clinical 
outcome. The standard six-month regimen was effective 
regardless of HIV infection. The potential benefits from 
adjunctive corticosteroids in the management of effusive 
tuberculous pericarditis could not be demonstrated in 
this three-year study.
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Pericardial disease accounts for about 10% of all patients 
who are hospitalised for cardiac impairment in develop-
ing countries,1 the most common cause being tuberculosis 
(TB). Before the introduction of anti-tuberculous drugs 
and improved anaesthetic and surgical techniques, tubercu-
lous pericarditis was usually fatal. The mortality has since 
decreased to between 17 and 40%.2-4 
Tuberculous pericarditis is routinely treated with pericar-
diocentesis5 and chemotherapeutic agents (including isoni-
azid, pyrazinamide, rifampicin and ethambutol).6 Although 
national guidelines recommend six months of intensive 
therapy,6 some experts recommend longer regimens ranging 
from nine7,8 to 129 months. Uncertainty exists as to whether 
the treatment duration should be altered in human immuno-
deficiency virus (HIV)-positive individuals. Higher rates of 
side effects from standard treatment regimens and higher 
relapse rates have been described in these patients,10 although 
this finding has not been consistent.11 
The use of adjunctive corticosteroid therapy, together 
with anti-tuberculous drugs remains topical in the treatment 
of tuberculous pericarditis. Rapid improvement of symptoms 
and reduced mortality have been suggested following the use 
of oral adjunctive corticosteroids.2-4,12-14 However, their use in 
HIV-positive individuals may increase the risk of bacterial 
and viral infections.15,16 
Maisch et al.17 demonstrated that side effects of systemic 
corticosteroid therapy could be avoided by treating autore-
active pericardial effusion with intrapericardial installation 
of 200 mg (5 ml) of the relatively nonresorbable cortico-
steroid steroid triamcinolone hexacetonide. Using a similar 
approach, Quigg18 successfully treated patients with uraemic 
pericardial effusions by pericardiocentesis with an indwell-
ing catheter followed by a stat instillation of triamcinolone 
hexacetonide into the pericardial space. 
Given the potential benefits of adjunctive corticosteroids 
and the possibility of achieving these benefits without the 
risk of the systemic effects of an 11-week course of high-
dose oral corticosteroids, we decided to test the effects of 
intrapericardial triamcinolone in patients with tuberculous 
pericardial effusion who had been on antituberculous therapy 
for at least 48 hours and the daily aspirate was less than 100 
ml. The triamcinolone (5 ml) was installed prior to removal 
of the indwelling pericardial catheter. 
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Objectives
The objectives of this study were: (1) to assess the role of 
adjunctive corticosteroid therapy with regard to mortality and 
the prevention of constrictive pericarditis; (2) to compare the 
administration of conventional oral corticosteroid therapy 
with intrapericardial triamcinolone hexacetonide; and (3) to 
assess the impact of HIV co-infection on the clinical course 
of patients with tuberculous pericardial effusions, as well as 
the effects of therapy in these patients. 
Methods
Patients presenting to the Cardiology Unit of Tygerberg 
Academic Hospital, Western Cape with large tuberculous 
pericardial effusions requiring diagnostic and/or therapeutic 
pericardiocentesis from February 1997 to June 2000 were 
screened for possible enrolment into this study. The study 
was approved by the ethics committee of Stellenbosch 
University and was conducted in accordance with the 
Declaration of Helsinki. All patients gave written informed 
consent and received counselling for HIV antibody testing. 
Baseline demographic, clinical, echocardiographic and elec-
trocardiographic data were also obtained.
Patient selection and management
All patients met the following inclusion criteria: (1) age 13 
to 75 years; (2) large pericardial effusion on echocardiog-
raphy (epi-pericardial distance > 10 mm); (3) pericardial 
aspirate with protein content > 30 g/l; (4) pericardial fluid 
adenosine deaminase (ADA) activity > 35 U/l. Patients with 
CD4 counts < 200 cells/μl were excluded due to uncertainty 
as to the effects of corticosteroids on immuno-compromised 
patients with TB with regard to risk for disseminated disease. 
In addition, patients presenting with signs of constrictive 
pericarditis or requiring pericardial surgery within the first 
five days of admission were excluded.
The pericardial effusion was drained by echocardiograph-
ically guided aspiration via an indwelling pigtail catheter;19,20 
the intention of this procedure was complete pericardial 
drainage. Chest radiography (CXR) was performed there-
after to exclude a pneumothorax and to evaluate the lung 
fields. The patient was then admitted into a general medical 
ward. The catheter was kept in situ to allow daily intermittent 
drainage and was removed when the daily aspirate was < 100 
ml, when it became blocked, or when there was evidence 
of localised skin infection. During hospitalisation, patients 
were examined twice daily for fever, change in haemody-
namic status, and clinical evidence of localised skin and/or 
pericardial infection. 
A standard short-course anti-tuberculous regimen was 
initiated according to national guidelines, namely a combina-
tion of rifampicin, isoniazid, pyrazinamide and ethambutol 
for two months, followed by rifampicin and isoniazid for a 
further four months.6 Patients were then randomly assigned as 
per a predetermined randomisation schedule for 100 patients 
on a 3:3:4 basis. Numbers were drawn from a hat, stored on 
a list on a computer and provided to the treating physician 
with the assigned treatment by a non-clinical administra-
tor. The randomisation code remained concealed and was 
not revealed to the investigators or the study subjects until 
completion of the study. The unblinded, independent physi-
cian administered one of the following randomly assigned 
treatment options: 
● Triamcinolone: 200 mg (5 ml) intrapericardial triamci-
nolone hexacetonide (n 5 17).
● Prednisone: oral prednisone plus intrapericardial placebo 
(5 ml 0.9% saline solution; n 5 16). Oral prednisone 
was started at 60 mg/day for four weeks, followed by 30 
mg/day for four weeks, 15 mg/day for two weeks and 5 
mg/day for one week.
● Placebo: 5 ml intrapericardial 0.9% saline (n 5 24). 
Triamcinolone was injected directly into the pericardium 
just prior to the removal of the indwelling catheter. Due to 
limited resources, an oral placebo was not used in conjunc-
tion with the intrapericardial triamcinolone. 
Patients were discharged on anti-tuberculous therapy and 
pyridoxine, with or without adjunctive prednisone. HIV-
positive patients also received daily oral cotrimoxazole; due 
to the prevailing national policy at the time of this study, 
none of these patients received antiretroviral therapy.
Laboratory investigations
Pericardial fluid was analysed for biochemistry,21 ADA 
activity,22 cytology, differential leukocyte count, and micro-
biology (Gram and auramine staining followed by micros-
copy and TB culture). Two morning samples of expectorated 
sputum were collected for direct microscopy and TB culture. 
Mycobacterium tuberculosis isolates were tested for suscep-
tibility to isoniazid and/or rifampicin. Blood was analysed 
for haematology (full-blood cell count and differential leuko-
cyte count), biochemistry (urea, creatinine, liver function 
tests and thyroid function tests), and serology [C-reactive 
protein (CRP), rheumatoid factor, antinuclear factor and 
antistreptolysin-O titre (ASOT)]. All patients were tested 
for HIV. CD4 lymphocyte counts were requested in all HIV-
positive patients. 
Follow-up assessment
Patients were assessed one month after discharge and thereaf-
ter at three-monthly intervals for a minimum of one year. At 
follow-up visits, patients were assessed clinically for features 
of ongoing TB, immunodeficiency, pericardial disease (effu-
sion, tamponade and constriction), side effects of medication 
(anti-tuberculous drugs and prednisone), general sense of 
wellbeing, and functional capacity. Therapeutic response 
was assessed as: (1) absence, improvement, or worsening 
of exercise tolerance, dyspnoea, cough, ankle swelling, 
abdominal discomfort, chest pain, fever, night sweats, and/
or weight loss; (2) absence, improvement, or worsening 
of oedema, ascites, hepatomegaly, pleural effusion, raised 
jugular venous pressure (JVP), tachycardia, hypotension, 
pulsus paradoxus, Kussmaul’s sign, pericardial rub, and/or 
pericardial knock; (3) evidence of infection at the puncture 
site and/or the pericardial space; and (4) echocardiographic 
Cardiovascular Journal.indd   234 11/7/06   9:56:14 AM
CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 17,  No. 5, September/October 2006 235
evidence of persisting or re-accumulated pericardial fluid or 
pericardial constriction and the subsequent need for pericar-
diectomy. Echocardiography was performed at baseline, at 
the first follow-up, and thereafter as clinically indicated. 
Outcome measures
The primary endpoint was all-cause mortality. Secondary 
endpoints included: (1) death attributed to pericarditis; (2) 
disability related to pericardial disease at one-year follow-up 
visit, where disability was defined as a history of restricted 
physical activity [using New York Heart Association (NYHA) 
functional class]; (3) development of effusive constriction; 
and (4) development of fibrous constrictive pericarditis 
requiring pericardiectomy. The diagnosis of constrictive 
pericarditis was made on the basis of a combination of 
clinical23 and echocardiographic features.24 These included 
abrupt posterior motion of the interventricular septum in 
early diastole, abrupt posterior motion during atrial systole, 
reduced amplitude of left ventricular posterior wall motion, 
premature pulmonary valve opening, dilatation of the hepatic 
veins and inferior vena cava, and characteristic Doppler 
patterns of transvalvular and central venous flow velocities 
during respiration.25 Patients did not undergo routine cardiac 
catheterisation to establish evidence of constriction.
Statistical analysis
Interval (continuous) variables are expressed as mean (stand-
ard deviation, SD). Statistical analysis of continuous vari-
ables was done with the Mann-Whitney U-test. Non-para-
metric data were expressed as median (range). Statistical 
analysis of these variables was done with the Kruskall-Wallis 
one-way ANOVA tests and chi-square testing to establish 
statistical significance. A p-value < 0.05 was considered 
statistically significant. Bonferroni (all pair-wise) multiple 
comparison and the Kruskall-Wallis multiple-comparison 
z-value tests were used to establish statistically significant 
differences between groups. For the Kruskall-Wallis test, 
medians were regarded as being significantly different if 
the z-value exceeded 1.960; for the Bonferroni test, medians 
were considered significantly different if z-values were > 
2.394. All statistical analyses were done using Statistica 
version 6.0.
Results
A total of 134 patients were admitted to Tygerberg Academic 
Hospital with large pericardial effusions requiring pericar-
diocentesis between February 1997 and June 2000. Ninety-
five individuals (70.9%) were diagnosed with pericardial 
TB, including 47 who tested HIV positive (49.5%). Based 
on pre-determined eligibility criteria, 57 patients (60.0%) 
were enrolled in the study. The age of study subjects ranged 
from 17 to 66 years, and included 23 females and 34 males. 
Demographic and clinical data are summarised in Table I. 
Reasons for patient ineligibility and the clinical outcomes of 
these patients are shown in Table II. The mean (SD) follow-
up period was 14.2 (2.3) months. Each patient received the 
randomly assigned treatment and results were evaluated on 
an intent-to-treat basis. 
Forty of the 57 patients (70.0%) had microbiological 
and/or histological evidence of TB, the remaining 17 patients 
(30.0%) were diagnosed by clinical and supportive labora-
tory data. Twenty-one of these patients (37.0%) were HIV 
positive. Baseline demographic, radiographic, electrocardio-
TABLE I. DEMOGRAPHIC AND CLINICAL  
DATA OF STUDY POPULATION
 
Demographic data
Prednisone
(n 5 16)
Triamcinolone
(n 5 17)
Placebo
(n 5 24)
Females 7  4 12
Males 9 13 12
HIV-seropositive  
patients
9  6   6
Mean age (SD) in years 34.4 (9.86) 38.6 (10.16) 33.3 (15.86)
Range of age (in years) 17–58 22–66 17–66
Symptoms
Fever (%) 13 (81) 12 (71) 18 (75)
Night sweats (%) 7 (44) 7 (41) 10 (42)
Weight loss (%) 13 (81) 13 (76) 19 (79)
Anorexia (%) 12 (75) 12 (71) 19 (79)
Dyspnoea (%) 15 (94) 16 (94) 22 (92)
Chest pain (%) 6 (38) 4 (24) 7 (29)
Cough (%) 14 (88) 15 (88) 20 (83)
Physical signs
Lymphadenopathy (%) 5 (31) 4 (24) 7 (29)
Soft cardiac sounds (%) 13 (81) 14 (82) 20 (83)
Hepatomegaly (%) 10 (63) 11 (65) 16 (67)
Peripheral oedema (%) 6 (38) 6 (35) 11 (46)
Ascites (%) 2 (13) 2 (12) 3 (13)
Tachycardia (%) 13 (81) 13 (76) 20 (83)
Pulsus paradoxus (%) 3 (19) 5 (29) 7 (29)
Kussmaul’s sign (%) 2 (13) 2 (12) 3 (13)
Jugular venous  
pressure > 4 cm (%)
13 (81) 15 (88) 20 (83)
Systolic BP < 100 
mmHg (%)
1 (6) 1 (6) 1 (4)
SD 5 standard deviation; BP 5 blood pressure; HIV 5 human 
immunodeficiency virus.
TABLE II. SUMMARY OF INELIGIBLE PATIENTS  
PRESENTING WITH TUBERCULOUS  
PERICARDITIS (n 5 38)
Exclusion criteria
Number of 
patients
(n 5 38)
Baseline 
constriction 
(n 5 6)
Deaths
(n 5 16)
CD4 cell count  
< 200 cells/µl
21 3 4
Lymphocyte count  
< 0.8 × 109/l
  4 0 3
Disseminated TB/ 
lymphocyte count  
< 0.8 × 109/l
  1 0 1
Early death/lymphocyte 
count < 0.8 × 109/l
  1 0 1
Early pericardial surgery   5 2 1
Blocked drainage tube   1 0 1
Left ejection fraction  
< 35%
 2 1 2
Severe lung disease   3 0 3
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graphic and echocardiographic findings were similar between 
the three treatment groups, as were baseline diagnostic and 
other laboratory findings (including ADA results). 
Clinical endpoints and complications 
Complications and observations of study patients at follow-
up are presented in Table III. All patients had a good clinical 
response to initial pericardiocentesis. The duration of hospi-
talisation ranged from four to 30 days; although the hospi-
talisation duration was slightly shorter in the two steroid 
groups compared to the placebo group, the difference was 
not statistically significant. 
There were no significant differences in the number of 
patients in each group that experienced minor complications 
such as localised pain, leakage at wound site, and local skin 
infection. Two patients developed transient jaundice but still 
completed six months of anti-tuberculous therapy. Thirteen 
cases of infection were recorded during the follow-up period, 
including oral candidiasis (n 5 5), local skin infection (n 
5 4), Herpes labialis (n 5 2), and Varicella zoster (n 5 
2). Although these events occurred more frequently in the 
combined corticosteroid group (n = 9; 27.2%) than in the 
placebo arm (n 5 4; 16.7%), the difference was not statisti-
cally significant (p 5 0.07). 
 Two male patients (both HIV negative) developed effu-
sive-constrictive pericarditis, which was diagnosed clinically 
and confirmed echocardiographically at the first follow up. 
Both patients were over 40 years of age with a positive 
smoking history; in addition, they both had evidence of 
pulmonary infiltrates on CXR and had been investigated for 
pulmonary TB in the month preceding pericardial aspira-
tion, suggesting the possibility of a more chronic form of 
pericardial TB. One patient (prednisone group) underwent 
surgical pericardial fenestration at six weeks, followed by 
total pericardiectomy at four months, and was entirely well 
at his one-year follow up. The other patient (triamcinolone 
group) had relatively mild features and refused surgery. He 
was managed conservatively, and the features of constric-
tion improved progressively and had subsided by the one-
year follow up. Echocardiography demonstrated pericardial 
thickening, which was still present at the two-year follow up, 
but not accompanied by features of constriction. 
Seven patients (12.0%) complained of reduced levels of 
activity at their one-year follow up. Three of these patients 
(42.9%, all HIV positive) had no cardiac abnormalities, and 
tests for disseminated TB and other opportunistic infections 
were negative. The other four patients (57.1%, of which one 
was HIV positive) were found to have an increased JVP. 
Echocardiography confirmed cardiac abnormalities: two had 
pericardial thickening but no definitive evidence of constric-
tion; the other two had left ventricular impairment with mild 
to moderate mitral and tricuspid regurgitation. 
The distribution of complications was similar between the 
three treatment arms (Table III). No deaths were recorded 
for the study population, but nine patients (16.0%) failed to 
attend their follow-up appointments at six and 12 months. 
None of these patients were admitted to Tygerberg Academic 
Hospital or any other public hospitals in the region for a peri-
od of two years after enrolment and all efforts to trace them 
failed. In addition, their names did not appear on the national 
death registry. The age distribution of these ‘non-attendees’ 
ranged from 17 to 58 years. Four of the nine patients were 
HIV positive with baseline CD4 counts of 392, 214, 256 and 
243 cells/µl, respectively. 
An analysis of the outcomes of the 38 TB patients who 
were excluded from the study is presented in Table II. All 
of these patients were treated by closed pericardiocentesis 
and concurrent early initiation of anti-tuberculous therapy. 
Patients with effusive constrictive pericarditis were treated 
by pericardial fenestration and adjunctive oral prednisone 
based on published recommendations.13,14 
Discussion
The present study suggests that echocardiographically guided 
closed pericardiocentesis with intermittent daily aspiration in 
combination with early initiation of directly observed antitu-
berculous therapy results in excellent outcomes in patients 
with effusive pericardial TB, irrespective of HIV status. Only 
two cases of effusive constrictive pericarditis developed 
during the first six months after enrolment. Both patients did 
well; one required total pericardiectomy due to symptomatic 
constriction, whereas the other improved without surgical 
intervention. The study was underpowered to detect signifi-
cant effects of adjunctive corticosteroids and a multi-centred 
study or a meta-analysis of similar studies would be required 
TABLE III. COMPLICATIONS AND OBSERVATIONS OF 
TRIAL PATIENTS AT FOLLOW UP (n 5 57)
Prednisone
(n 5 16)
Triamcinolone
(n 5 17)
Placebo
(n 5 24)
Complications in hospital
Local pain 3 3 4
Repeat pericardiocentesis 1 0 1
Leakage at skin insertion 1 1 2
Local skin infection 0 1 1
Duration of 
hospitalisation
Mean (SD) days 9.9 (5.1) 10.5 (4.4) 11.2 (5.3)
Range in days 4–21 4–19 4–30
Complications as  
out-patient
Herpes labialis 1 0 1
Varicella zoster 1 1 0
Local skin infection 1 1 0
Effusive constriction 1 1 0
Fibrous constriction 1 0 0
Left ventricular aneurysm 0 1 0
Surgical intervention
Pericardial fenestration 1 0 0
Total pericardiectomy 1 0 0
Status at 1-year follow-up
Reduced level of activity 2 2 3
Raised JVP 1 1 2
Hepatomegaly 0 1 0
Failure to attend follow-
up visit
4 1 4
JVP 5 jugular venous pressure.
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to assess larger numbers of patients in order to evaluate the 
potential benefit of adjunctive corticosteroids.
The study also demonstrated that secondary skin infec-
tion occurs rarely when an aseptic technique is applied and 
no differences in the frequency of skin sepsis were noted 
between the various treatment groups. The incidence of 
systemic infections or HIV-associated complications, such 
as opportunistic infections or malignancies was also simi-
lar in the three treatment categories. The use of adjunctive 
corticosteroids led to shortened hospitalisation with a mean 
(SD) duration of days in hospital for the prednisone, triam-
cinolone and placebo groups of 9.9 (5.1), 10.5 (4.4) and 11.2 
(5.3), respectively. Differences between the two adjunctive 
corticosteroid and the placebo groups were statistically 
insignificant. 
The results of this study support the use of routine anti-
tuberculous therapy for six months in both HIV-positive 
and -negative patients. There were no associated cases of 
multi-drug resistance, reactivation, or dissemination of TB. 
HIV-infected patients had very similar outcomes to those 
who were HIV negative and based on our results, there is no 
reason to support prolonged treatment duration in individu-
als who have CD4 counts > 200 cells/µl. 
There are a number of published reports of small series 
of patients demonstrating the beneficial effect of prednisone 
in patients with tuberculous pericarditis.13,14,26,27 Contrary to 
these reports, the use of adjunctive steroids did not result in 
improved clinical outcome in this series of patients with effu-
sive tuberculous pericarditis. Effusive-constrictive pericardi-
tis was an exclusion criterion in the present study, whereas 
other studies have described features suggestive of estab-
lished or threatening effusive-constrictive pericarditis.13,14 In 
the former Transkei, effusive constriction was considered to 
be a more common clinical variety than pericardial effusion 
or classical fibrous constrictive pericarditis.28 
It is therefore necessary to recognise that different inter-
ventions may be required for specific clinical phases of the 
same disease. In an observational study, patients who had 
only 80 to 100 ml of fluid aspirated before treatment with 
high doses of oral prednisolone (including four weeks of 
120 mg daily), and where standard TB therapy was initiated, 
had rapid resolution of their effusions.29 A potential place 
for adjunctive corticosteroids may therefore possibly be for 
those patients who present relatively late and have features 
of effusive-constrictive disease at presentation,13,14 or those in 
whom pericardiocentesis is unsuccessful.30 It has also been 
suggested that corticosteroids be reserved for critically ill 
patients with recurrent large effusions who do not respond 
to pericardial drainage and anti-tuberculous drugs alone. In 
view of the results of our series of patients, no benefit was 
observed by using intrapericardial triamcinolone. 
The present study also suggests that the mortality of HIV-
infected individuals (CD4 counts > 200 cells/µl) does not 
differ significantly from those who are HIV negative. This 
contradicts earlier reports suggesting a significantly higher 
mortality in HIV-infected individuals.31 In the present study, 
adjunctive steroids resulted in a tendency towards a higher 
number of minor infections; however, none of the patients 
developed oesophageal candidiasis, cryptococcal meningitis, 
or other more serious opportunistic infections, malignancies, 
septicaemia or pneumonia. 
Other researchers have found potentially harmful side 
effects related to the use of steroids in HIV-infected indi-
viduals, including a higher incidence of bacterial infections, 
Herpes simplex and Herpes zoster reactivation, and poten-
tially the development of Kaposi’s sarcoma.15,16,32 In a non-
randomised study of TB in HIV-positive patients, Elliott and 
colleagues16 reported increased risk for Herpes zoster and 
Kaposi’s sarcoma in patients treated with prednisone, but 
in the study of Hakim and colleagues,33 Kaposi’s sarcoma 
occurred only in patients who were not on steroids. 
None of the HIV patients in the present study devel-
oped constriction and it has been postulated that the rate 
of constriction is reduced by HIV infection.33 Hakim and 
colleagues33 observed a trend towards improved survival but 
no reduction in the occurrence of constriction in the adjunc-
tive steroid group. In keeping with our results, an updated 
version of the Cochrane Systematic Review (which includes 
Hakim’s study) revealed that the results of all published stud-
ies are still inconclusive and that there is uncertainty regard-
ing the effectiveness of steroids in patients with tuberculous 
pericarditis.34 
Our study has a number of weaknesses; most notably the 
fact that 16.0% of patients did not attend their six-month and/
or one-year follow-up visits and that data on mortality and 
constriction may therefore be incomplete. The poor follow-
up rate probably reflects the impact of migratory lifestyles on 
healthcare in poorer socio-economic regions of South Africa. 
It could also be argued that an oral placebo should have been 
used in combination with the intrapericardial placebo. 
At the time of planning the study, the role of cortico-
steroids in HIV-infected patients was unclear and it was 
decided to expose only those with CD4 counts > 200 cells/µl. 
Twenty-one potential patients were not enrolled due to this 
reason. An analysis of these patients confirmed an increased 
rate of morbidity and mortality due to non-cardiac compli-
cations. There was a dramatically increased mortality in 
patients who had been excluded from the trial on the basis 
of low CD4 and/or total lymphocyte counts. Retrospectively, 
it could be argued that these patients should have been 
included in the study. 
Conclusion
Intrapericardial and systemic corticosteroids were well 
tolerated, but did not improve the outcome in these selected 
patients. The standard six-month treatment regimen was 
effective regardless of HIV infection. This single-centre 
study was underpowered to detect significant effects of 
adjunctive corticosteroids. Further placebo-controlled trials 
are warranted but should be conducted at several centres 
using the same protocol, as single-centre studies are unlikely 
to answer these questions. Patients with effusive constrictive 
disease should be included, as well as those with CD4 counts 
< 200 cells/µl. At present, there is no conclusive evidence for 
the routine use of adjunctive corticosteroids, which should 
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be reserved for critically ill patients with recurrent large 
effusions who do not respond to pericardial drainage and 
anti-tuberculous drugs alone.30 
The authors thank Dr ME Carstens and A Jacobs for data collection, Dr 
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